Coherus Gets Goal Date On US Adalimumab Biosimilar
Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target
A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.
